bioAffinity Technologies, Inc.
BIAF
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $2.0M
$4.87
▼ -3.75%
P/E
—
Mkt Cap
$2.0M
52-Wk Range
$4.87–$202.50
52-Week Range
$4.87 - $202.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 95.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary non-invasive diagnostic technology
- Early-stage cancer detection capabilities
- Integrated diagnostic and therapeutic approach
- Specialized focus on high-mortality cancer types
Bear Case
1 risk
- Low volatility (beta -1.1).
Growth
Moderate growth ahead
Increasing lung cancer screening adoption and regulatory approvals
Value
Valuation data unavailable
Momentum
Falling
-80.6% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying BIAF right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 18, 2026
AUG 7, 2026
Reported EPS of -$0.64 vs -$2.10 consensus (+69.5% surprise). Revenue of $1.5M vs $1.7M expected (-11.2%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+69.5%
Revenue trend · last 8Q
—
—
-23%
-47%
-38%
-28%
-27%
+19%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.4M
$2.2M
$1.9M
$1.3M
$1.4M
$1.6M
$1.4M
$1.5M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-222.8%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BIAF stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related